MPT: Ticagrelor Fails to Improve on Clopidogrel After Switch

ACC Conference Reporter

ESC 2017 | BARCELONA — Switching from clopidogrel (Plavix) to ticagrelor (Brilinta) for dual antiplatelet therapy (DAPT) had no benefit in patients stented for an acute coronary syndrome (ACS), a Dutch center reported here, in contrast to results from the PLATO trial 8 years ago. Read More >>>

Keywords: ESC2017, ESC Congress


< Back to Listings